Early access
Sign in
Taking people in FinlandPhase 4

Tests a precision treatment plan for high-risk rectal cancer patients

Tests a precision systemic treatment approach in adults with high-risk rectal cancer.

Key facts

Who runs it
HUS-Yhtymae
Where
Helsinki and Tampere, FinlandSee the 2 sites
Registry title
Systemic Neoadjuvant and adjuvant Control by Precision medicine in rectal cancer (SYNCOPE) – approach on high-risk group to reduce metastases
Status
Recruiting
Phase
Phase 4
People taking part
100 people, planned
Started
1 Dec 2024
Expected to end
31 Dec 2026
Type of study
Interventional
Record updated
24 September 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with rectal adenocarcinoma who are in good general condition and are judged by the care team to need radiotherapy or chemoradiotherapy and to be able to take CAPOX.

Age
18 years or older
Sex
All sexes can join
Disease stage
Rectal adenocarcinoma with mrEMVI+ (tumour growth into veins around the rectum seen on MRI). The care team judges that radiotherapy or chemoradiotherapy is needed.
Biomarker or test result
mrEMVI+ on MRI is required. Tumours with deficient MMR status cannot join.

Main reasons for not taking part

  • Deficient MMR status
  • Non-DPYD genotype
  • A reason why capecitabine, oxaliplatin or radiotherapy cannot be given
  • Blood tests that do not show adequate circulatory function
  • Blood tests that do not show adequate liver and kidney function for chemotherapy

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • rectal adenocarcinoma, 2) WHO performance status 0-1, assessed by the MDT to be able to undergo CAPOX (capecitabine and oxaliplatin) treatment, 3) mrEMVI+ and 4) assessed by the MDT to require either RT or CRT by the current standards. In general, indications for clinical rectal carcinoma MDT to recommend RT or CRT are: T3-4 tumor at mid- or low rectum location, involvement of lymph nodes, threatened operative margin or mrEMVI

Who cannot take part

  • 1.) deficient MMR status, non-DPYD genotype 2) a contraindication to capecitabine, oxaliplatin or RT, 3) failing in blood tests that describe the adequate circulatory 4) liver and kidney function for chemotherapy

Where in Finland

  • HUS-YhtymaeHelsinki, FinlandTaking people
  • Tampere University HospitalTampere, FinlandTaking people

About the trial

What the trial wants to find out

Applying a systemic control with precision approach over the course of the rectal cancer therapy is logistically feasible Applying a systemic control and precision approach as a treatment strategy, recurrence-free survival of rectal cancer patients is improved

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Systemic Neoadjuvant and adjuvant Control by Precision medicine in rectal cancer (SYNCOPE) – approach on high-risk group to reduce metastases
Plain-language title
Tests a precision treatment plan for high-risk rectal cancer patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
24 September 2024